SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health. NIH Consensus Development Conference Statement: management of hepatitis C. HEPATOLOGY 2002; 36( Suppl 1): S3S20.
  • 2
    Feld, JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967972.
  • 3
    Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 2338.
  • 4
    Upchurch DA, Shankarappa R, Mullins JI. Position and degree of mismatches and the mobility of DNA heteroduplexes. Nucleic Acids Res 2000; 28: E69.
  • 5
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepatitis 2007; 14: 721729.
  • 6
    Higgins DG, Sharp PM. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 1988; 73: 237244.
  • 7
    Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999; 41: 9598.
  • 8
    Clauset A, Shalizi CR, Newman MEJ. Power-law distributions in empirical data. 2007; http://arxiv.org/abs/0706.1062.
  • 9
    Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol 2006; 78: 446451.
  • 10
    Ross RS, Viazov S, Roggendorf M. Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 5′ untranslated and the core regions. J Virol Methods 2007; 143: 153160.
  • 11
    Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004; 40: 831836.
  • 12
    Shan-Lu Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, et al. HIV quasispecies and resampling. Science 1996; 273: 413417.
  • 13
    Fan X, Solomon H, Poulos JE, Neuschwander-Tetri BA, Di Bisceglie AM. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am J Gastroenterol 1999; 94: 13471354.
  • 14
    Fan X, Lyra AC, Tan D, Xu Y, Di Bisceglie AM. Differential amplication of hypervariable region 1 of hepatitis C virus by partially mismatched primers. Biochem Biophys Res Commun 2001; 284: 694697.
  • 15
    Torres-Puente M, Bracho MA, Jimenez N, Garcia-Robles I, Moya A, Gonzalez-Candelas F. Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J Gen Virol 1003; 84: 23432350.
  • 16
    Ferenci P, Fried M, Shiffman M, Smith C, Marinos G, Gonçales F, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • 17
    Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharm Therap 2006; 23: 10431054.
  • 18
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 19
    Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 10151023.
  • 20
    Nei M. Phylogenetic analysis in molecular evolutionary genetics. Annu Rev Genet 1996; 30: 371403.
  • 21
    Mondelli MU, Cerino A, Meola A, Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. J Biosci 2003; 28: 305310.
  • 22
    Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antivir Res 2001; 52: 153159.
  • 23
    Bak P. How Nature Works: The Science of Self-organized Criticality. New York: Springer; 1999: 131.
  • 24
    Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49: 242247.
  • 25
    Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000; 7: 3642.
  • 26
    Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. HEPATOLOGY 1994; 20: 11211130.
  • 27
    Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. HEPATOLOGY 1995; 22: 3035.
  • 28
    Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108: 789795.
  • 29
    Nagasaka A, Hige S, Tsunematsu I, Yoshida J, Sasaki Y, Matsushima T, et al. Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy. J Med Virol 1996; 50: 214220.
  • 30
    Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. HEPATOLOGY 1992; 16: 619624.
  • 31
    Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. HEPATOLOGY 1996; 24: 10181023.
  • 32
    Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. HEPATOLOGY 1997; 25: 12501254.
  • 33
    Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez MT, et al. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection. HEPATOLOGY 1999; 29: 897903.
  • 34
    Nakazawa T, Kato N, Ohkoshi S, Shibuya A, Shimotohno K. Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J Hepatol 1994; 20: 623629.
  • 35
    Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, et al. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 2000; 74: 661668.
  • 36
    Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005; 79: 30713083.
  • 37
    Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002; 99: 30813086.
  • 38
    Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, et al. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2001; 289: 150163.
  • 39
    Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, Bracho MA, Garcia-Robles I, Wrobel B, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepatitis 2008; 15: 188199.
  • 40
    Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006; 193: 931940.
  • 41
    Domingo E. Quasispecies theory in virology. J Virol 2002; 76: 463465.
  • 42
    Biebricher CK, Eigen M. What is a quasispecies? Curr Top Microbiol 2006; 299: 131.
  • 43
    Bak P, Tang C, Wiesenfeld K. Self-organized criticality. Phys Rev 1998; 38: 364374.
  • 44
    Wang WK, Lin SR, Lee CM, King CC, Chang SC. Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol 2002; 76: 46624665.
  • 45
    Jerzak G, Bernard KA, Kramer LD, Ebel GD. Genetic variation in West Nile virus from naturally infected mosquitoes and birds suggests quasispecies structure and strong purifying selection. J Gen Virol 2005; 86: 21752183.